Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction

Legacy data show that ∼40% of children with acute lymphoblastic leukemia (ALL) were cured with limited antimetabolite-based chemotherapy regimens. However, identifying patients with very-low-risk (VLR) ALL remains imprecise. Patients selected based on a combination of presenting features and a minim...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2021-01, Vol.137 (1), p.20-28
Hauptverfasser:	Sidhom, Iman, Shaaban, Khaled, Youssef, Sarah H., Ali, Nesreen, Gohar, Seham, Rashed, Wafaa M., Mehanna, Mai, Salem, Sherine, Soliman, Sonya, Yassin, Dina, Mansour, Emad, Coustan-Smith, Elaine, Ribeiro, Raul C., Rivera, Gaston K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - administration & dosage Child Child, Preschool Clinical Trials and Observations Female Humans Infant Male Neoplasm, Residual - pathology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology Remission Induction - methods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Legacy data show that ∼40% of children with acute lymphoblastic leukemia (ALL) were cured with limited antimetabolite-based chemotherapy regimens. However, identifying patients with very-low-risk (VLR) ALL remains imprecise. Patients selected based on a combination of presenting features and a minimal residual disease (MRD) level
ISSN:	0006-4971 1528-0020
DOI:	10.1182/blood.2020007977